Environmental factors influencing the development and spread of resistance in erythromycin-resistant streptococcus pneumoniae

Environ Geochem Health. 2024 Nov 7;46(12):488. doi: 10.1007/s10653-024-02264-0.

Abstract

Bacterial drug resistance is becoming increasingly serious, this study aims to investigate the relationship between the resistance rate of erythromycin-resistant Streptococcus pneumoniae (SP) and reasons for the epidemic under complex geographical and climatic factors in China. Data spanning from 2014 to 2021, including drug resistance rates, isolate rates, meteorological variables, and demographic statistics, were collected from the China Antimicrobial Resistance Monitoring System, the China Statistical Yearbook and China Meteorological Website. Our analysis involved nonparametric tests and the construction of multifaceted regression models for rigorous multivariate analysis. Single-factor analysis revealed significant differences in the resistance rate and isolate rate of erythromycin-resistant SP across different regions characterized by Hu Huanyong lines or different climate types. Multivariate regression analysis indicated positive correlations between the drug resistance rate and temperature, Subtropical climate, Gross Domestic Product (GDP), Hu Huanyong line, and the highest temperature in the past period (Tm); the isolate rate showed a positive correlation with regional GDP and a negative correlation with monsoon climate. The model developed in this study provides valuable insights into the resistance rate and potential relationships of erythromycin-resistant SP under complex meteorological conditions in China.

Keywords: China Mainland; Climate; Drug resistance rate; Erythromycin-resistant Streptococcus pneumoniae; Geographical distribution.

MeSH terms

  • Anti-Bacterial Agents* / pharmacology
  • China
  • Climate
  • Drug Resistance, Bacterial*
  • Erythromycin* / pharmacology
  • Humans
  • Pneumococcal Infections / epidemiology
  • Pneumococcal Infections / microbiology
  • Streptococcus pneumoniae* / drug effects

Substances

  • Erythromycin
  • Anti-Bacterial Agents

Grants and funding